Skip to main content
  • Cobra Stent with Short DAPT Does Not Reduce Bleeding or Show Noninferiority in Thrombosis vs. DES with standard DAPT in HBR Patients

    As treatment for high-bleeding-risk (HBR) patients with acute or chronic coronary syndromes, the Cobra PzF nanocoated coronary stent followed by 2 weeks of dual antiplatelet therapy (DAPT) did not reduce bleeding and failed to demonstrate noninferiority to standard drug-eluting stents (DES) with 3 to 6 months of DAPT with respect to thrombotic events, according to study results presented Saturday at the TCT Connect virtual conference.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details